Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.5 CAD | 0.00% | +4.90% | -16.20% |
Apr. 11 | Oncolytics Biotech Inc. Announces the Submission of a Type C Meeting Request to the FDA | CI |
Apr. 11 | Oncolytics Biotech Down 1.8% In US Premarket As Submits Type C Meeting Request to FDA | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.20% | 82.88M | |
+1.34% | 42.86B | |
+11.89% | 42.74B | |
+45.09% | 41.36B | |
-8.83% | 27.68B | |
+7.28% | 25.15B | |
-23.61% | 18.63B | |
+29.52% | 12.37B | |
-2.21% | 11.92B | |
+7.34% | 11.21B |
- Stock Market
- Equities
- ONC Stock
- News Oncolytics Biotech Inc.
- RBC Reiterates Positive Outlook For Oncolytics -- Maintains $6 Target, Outperform/Speculative Risk Rating